-
Tipo NewsRICERCA PARTNER
-
FonteSIMPLER
-
Del
The laboratory of inorganic chemistry of a Greek university, which is active in insulin mimetic activity is looking for partners to set up a proposal regarding the understanding of the molecular mechanisms of novel metallodrugs exhibiting insulinomimetic activity. They are looking for a research institute or university with expertise in metabolic syndrome research in order to submit a proposal to the call H2020-SC1-PM-09–2016 (NB: Work Programme ancora in versione draft): New therapies for chronic diseases.
Metal-containing pharmaceuticals have been established over the past century and are currently being used to treat other diseases. In particular for the treatment of Diabetes Mellitus (DM) II, metallodrugs have the following advantages:
- They overcome insulin resistance and enhance insulin action.
- They are novel anti-diabetic agents based on endogenous and naturally-occurring metal ionic species of adipogenic potential and glucose catabolism. Endogenous and exogenous metal ionic factors have been shown to enhance physiological processes linked to cellular aberrations (in a number of diseases).
- Well-defined metallodrugs are atoxically, chemically and biologically suitable to overcome specific problems with insulin-linked glucose metabolism.
- They can provide a structure-specific assessment of insulin-like effects in insulin sensitive tissues, which is the key to glucose uptake.
- They show mechanistic delineation of insulin mimetic action.
Per ulteriori informazioni finalizzate ad attivare una partnership, segnaliamo che è possibile:
- scrivere all'indirizzo e-mail [email protected], se localizzati nella regione Emilia Romagna
- individuare l'ente di riferimento per la propria regione sul sito ufficiale di Enterprise Europe Network, se localizzati in altre regioni d'Italia riportando, in ogni caso, il codice: RDGR20150916002